From Name:
From Email:
To Name:
To Email:

Optional Message:


Insurance Appeals, Denials Delay Patient Access to PCSK9 Inhibitors

from Healio

High denial rates and long processes from insurance providers prohibit high-risk patients with familial hypercholesterolemia and clinical atherosclerotic CVD from accessing PCSK9 inhibitors, according to a paper in Clinical Cardiology. "In addition to the patients not being treated with an appropriate medication, one of the most egregious things that's occurring right now is that the payers, by denying these prescriptions, are undermining the patient–doctor relationship, and there used to be sanctity in that relationship. There no longer is," Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, chief medical officer at Excel Medical Clinical Trials, clinical affiliate professor of biomedical science at Florida Atlantic University, Boca Raton and president of the American Society for Preventive Cardiology, and colleagues wrote in the paper. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063